Cargando…
Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives
Nanotechnology has been actively integrated as drug carriers over the last few years to treat various cancers. The main hurdle in the clinical management of cancer is the development of multidrug resistance against chemotherapeutic agents. To overcome the limitations of chemotherapy, the researchers...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898224/ https://www.ncbi.nlm.nih.gov/pubmed/33628022 http://dx.doi.org/10.2147/IJN.S289443 |
_version_ | 1783653821299294208 |
---|---|
author | Edis, Zehra Wang, Junli Waqas, Muhammad Khurram Ijaz, Muhammad Ijaz, Munazza |
author_facet | Edis, Zehra Wang, Junli Waqas, Muhammad Khurram Ijaz, Muhammad Ijaz, Munazza |
author_sort | Edis, Zehra |
collection | PubMed |
description | Nanotechnology has been actively integrated as drug carriers over the last few years to treat various cancers. The main hurdle in the clinical management of cancer is the development of multidrug resistance against chemotherapeutic agents. To overcome the limitations of chemotherapy, the researchers have been developing technological advances for significant progress in the oncotherapy by enabling the delivery of chemotherapeutic agents at increased drug content levels to the targeted spots. Several nano-drug delivery systems designed for tumor-targeting are evaluated in preclinical and clinical trials and showed promising outcomes in cancerous tumors’ clinical management. This review describes nanocarrier’s importance in managing different types of cancers and emphasizing nanocarriers for drug delivery and cancer nanotherapeutics. It also highlights the recent advances in nanocarriers-based delivery systems, including polymeric nanocarriers, micelles, nanotubes, dendrimers, magnetic nanoparticles, solid lipid nanoparticles, and quantum dots (QDs). The nanocarrier-based composites are discussed in terms of their structure, characteristics, and therapeutic applications in oncology. To conclude, the challenges and future exploration opportunities of nanocarriers in chemotherapeutics are also presented. |
format | Online Article Text |
id | pubmed-7898224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-78982242021-02-23 Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives Edis, Zehra Wang, Junli Waqas, Muhammad Khurram Ijaz, Muhammad Ijaz, Munazza Int J Nanomedicine Review Nanotechnology has been actively integrated as drug carriers over the last few years to treat various cancers. The main hurdle in the clinical management of cancer is the development of multidrug resistance against chemotherapeutic agents. To overcome the limitations of chemotherapy, the researchers have been developing technological advances for significant progress in the oncotherapy by enabling the delivery of chemotherapeutic agents at increased drug content levels to the targeted spots. Several nano-drug delivery systems designed for tumor-targeting are evaluated in preclinical and clinical trials and showed promising outcomes in cancerous tumors’ clinical management. This review describes nanocarrier’s importance in managing different types of cancers and emphasizing nanocarriers for drug delivery and cancer nanotherapeutics. It also highlights the recent advances in nanocarriers-based delivery systems, including polymeric nanocarriers, micelles, nanotubes, dendrimers, magnetic nanoparticles, solid lipid nanoparticles, and quantum dots (QDs). The nanocarrier-based composites are discussed in terms of their structure, characteristics, and therapeutic applications in oncology. To conclude, the challenges and future exploration opportunities of nanocarriers in chemotherapeutics are also presented. Dove 2021-02-17 /pmc/articles/PMC7898224/ /pubmed/33628022 http://dx.doi.org/10.2147/IJN.S289443 Text en © 2021 Edis et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Edis, Zehra Wang, Junli Waqas, Muhammad Khurram Ijaz, Muhammad Ijaz, Munazza Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives |
title | Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives |
title_full | Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives |
title_fullStr | Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives |
title_full_unstemmed | Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives |
title_short | Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives |
title_sort | nanocarriers-mediated drug delivery systems for anticancer agents: an overview and perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898224/ https://www.ncbi.nlm.nih.gov/pubmed/33628022 http://dx.doi.org/10.2147/IJN.S289443 |
work_keys_str_mv | AT ediszehra nanocarriersmediateddrugdeliverysystemsforanticanceragentsanoverviewandperspectives AT wangjunli nanocarriersmediateddrugdeliverysystemsforanticanceragentsanoverviewandperspectives AT waqasmuhammadkhurram nanocarriersmediateddrugdeliverysystemsforanticanceragentsanoverviewandperspectives AT ijazmuhammad nanocarriersmediateddrugdeliverysystemsforanticanceragentsanoverviewandperspectives AT ijazmunazza nanocarriersmediateddrugdeliverysystemsforanticanceragentsanoverviewandperspectives |